ライフサイエンスコーパス: viral particle

1 everal segments, each packaged in a distinct viral particle.

2 enerate free fluorescent proteins within the viral particle.

3 he integrity of viral capsid protein and the viral particle.

4 rus generates a membrane transport-competent viral particle.

5 rotein (MP)-RNA interfaces are used in every viral particle.

6 me release associated with destabilizing the viral particle.

7 nternal DNA pressure on the stability of the viral particle.

8 tides derived from proteins contained in the viral particle.

9 present only on the intact, fully assembled viral particle.

10 protein and is an essential component of the viral particle.

11 ampers the recognition of gB epitopes in the viral particle.

12 , Siglec-1 promotes attachment and fusion of viral particles.

13 nce of specific RNA segment subsets from the viral particles.

14 elucidated various asymmetric structures in viral particles.

15 ly reduces the number of excreted infectious viral particles.

16 ive cells and identified endocytic uptake of viral particles.

17 e incorporation of other viral proteins into viral particles.

18 ong term CRC cell cultivation in presence of viral particles.

19 the interface of the E dimers coating mature viral particles.

20 fficient production and spread of infectious viral particles.

21 rologous, non-viral RNAs to be packaged into viral particles.

22 i increased levels of viral proteins and new viral particles.

23 fficiently expressed and incorporated in the viral particles.

24 l membrane dictate active incorporation into viral particles.

25 osomes, and exclusion from newly synthesized viral particles.

26 ly, and their depletion increases infectious viral particles.

27 depletion by immunoblot analyses of purified viral particles.

28 ssociated herpesvirus with limited egress of viral particles.

29 immunogenic DB and inactivate contaminating viral particles.

30 selection resulting in a mixed population of viral particles.

31 o facilitate efficient production of progeny viral particles.

32 ontaining vesicles that were associated with viral particles.

33 ly a function of the cell line producing the viral particles.

34 reater infection efficiency than free single viral particles.

35 mune attack, and maintain the infectivity of viral particles.

36 or 3 doses of 10 mug chemically inactivated viral particles.

37 o an increase in the generation of defective viral particles.

38 SCRT) machinery to facilitate the release of viral particles.

39 and for detecting the presence of infectious viral particles.

40 genome pressure on the thermal stability of viral particles.

41 equate to differences in overall release of viral particles.

42 erted effort of infectious and noninfectious viral particles.

43 efense strategy that could otherwise degrade viral particles.

44 te mechanisms of nucleocytoplasmic egress of viral particles.

45 tiated from an exceptionally small number of viral particles.

46 rofile of single-stranded genomic RNA inside viral particles.

47 omic and subgenomic RNAs into three separate viral particles.

48 n of quaternary structures on the surface of viral particles.

49 or the encapsidation of full-length RNA into viral particles.

50 preferentially by the release of infectious viral particles.

51 ng filopodial protrusions possessing budding viral particles.

52 al neurons to study axonal transport of H129 viral particles.

53 impact on Env conformation at the surface of viral particles.

54 -defective Env that is not incorporated into viral particles.

55 trate that ASP is present on the surfaces of viral particles.

56 to determine the intrinsic mobility width of viral particles.

57 r pre-concentration of cells with high-titer viral particles.

58 ing machinery and do not effectively produce viral particles.

59 ic RNA and perturbs the morphogenesis of new viral particles.

60 administered in three dose levels--1x10(10) viral particles, 2.5x10(10) viral particles, and 5x10(10

61 Material type influenced bacterial and viral particle abundance and bacterial and metabolic (bu

62 We propose a model in which M45 delivered by viral particles activates NF-kappaB, presumably involvin

63 report that incorporation of CD4 into HIV-1 viral particles affects Env conformation resulting in th

64 Taken together, our data suggested that some viral particles after secondary envelopment accumulated

65 or low molecular-weight ligands, both in the viral particle and between the virus and its host.

66 relation between RNP localization within the viral particle and the formation of conical cores, sugge

67 on is linked to a direct association between viral particles and bacterial compounds as observed by m

68 Both vectors can be packaged into viral particles and be used to transduce cells, allowing

69 The majority of these cells do not produce viral particles and constitute what is referred to as th

70 ect damage to the viral envelope, disrupting viral particles and decreasing virus binding to, and inf

71 >3-fold more genome-containing noninfectious viral particles and delivered increased amounts of pp65

72 terial surface polysaccharides can stabilize viral particles and enhance transmission.

73 f virus specific antibodies are neutralizing viral particles and enhancing viral clearance.

74 concerns over the risk of aerosolization of viral particles and exposure of operating room staff to

75 reveals activated platelets, many containing viral particles and extracellular-DNA associated with pl

76 a markedly reduced ability to assemble into viral particles and had reduced antiviral activity.

77 s for the sparse Env copy number observed on viral particles and includes a 22-amino-acid, lentivirus

78 tastable complex expressed at the surface of viral particles and infected cells that samples differen

79 se-independent processes: encapsidation into viral particles and inhibition of reverse transcription.

80 onal evidence that M2-1 is incorporated into viral particles and is positioned between M and RNP.

81 d due to protein-protein interaction between viral particles and MTs.

82 us families and includes populations of both viral particles and naked viral genomes.

83 leads to clustering of HCV proteins because viral particles and replication complex vesicles cannot

84 re required for efficient incorporation into viral particles and that the particles contain a variabl

85 ng a direct interaction between the incoming viral particles and the dynein complex regulators.

86 Herpesviruses must amplify their DNA to load viral particles and they do so in replication compartmen

87 nv mutants for the ability to be enriched in viral particles and to perform other glycoprotein functi

88 However, direct examination of viral particles and virus-cell interactions is now possi

89 levels--1x10(10) viral particles, 2.5x10(10) viral particles, and 5x10(10) viral particles--with 20 p

90 ecules, along with an abundance of bacteria, viral particles, and eukaryotic cells.

91 which were shown to colocalize with incoming viral particles, and rearrangement of the actin cytoskel

92 tics, glycoprotein proportions on individual viral particles, and receptor-induced conformational cha

93 ocytosed material, replication and egress of viral particles, and regulation of inflammatory and immu

94 ction of viral RNAs, surface antigens, whole viral particles, antibodies and other potential biomarke

95 -loaded with magnetic nanoparticles to which viral particles are bound-is brought into proximity of t

96 Viral particles are endowed with physicochemical propert

97 Following internalisation, viral particles are found in CD63-positive endosomes rec

98 However, how H129 viral particles are transported in neurons, especially t

99 usly showed that a significant proportion of viral particles are transported to the Golgi apparatus a

100 ese viral proteins drives formation of a new viral particle as well as the activation of HIV protease

101 nv mutants for the ability to be enriched in viral particles as well as perform other glycoprotein fu

102 Viral particle assembly and budding processes represent

103 psid (NC) domains-drives different phases of viral particle assembly and egress.

104 interactions at the early stages of immature viral particle assembly in a p6-independent manner.

105 interfere not with DNA integration but with viral particle assembly late during HIV replication.

106 t deficiency of gH expression did not affect viral particle assembly or egress.

107 likely via transfer of the HCV RNA genome to viral particle assembly sites.

108 likely via transfer of the HCV RNA genome to viral particle assembly sites.

109 ocalization of viral RNAs, and inhibition of viral particle assembly.

110 ith henipavirus M proteins and contribute to viral particle assembly.

111 ing motor to encapsulate their genome during viral particle assembly.

112 or genomic RNA (gRNA) packaging and immature viral particle assembly.

113 signal transduction bring the coreceptor to viral particles at the cell surface, and could form the

114 To be packaged into viral particles at the plasma membrane, encapsidated vir

115 ral life cycle and for the production of new viral particle-based vaccines.

116 e transmitted via vesicles as populations of viral particles but also that this type of transmission

117 heparanase (HPSE) facilitates the release of viral particles by cleaving HS.

118 TNF reduced production of infectious viral particles by Huh-7 and HFLC, and thereby reduced t

119 ation of A3G, and reduced the infectivity of viral particles by increased packaging of A3G.

120 protein that blocks the release of enveloped viral particles by linking them to the membrane of produ

121 is the lowest LOD for analysis of influenza viral particles by the glycan-based device achieved so f

122 To test this, we generated defective viral particles by treatment with HIV-1 protease inhibit

123 that Vpu-mediated lowering of CD81 levels in viral particles can be critical to maintaining their inf

124 Computer simulations of complete viral particles can provide theoretical insights into la

125 The incoming viral particle carries a deamidase activity on its surfa

126 ibited a mean increase of 10(4.5) infectious viral particles compared to the titers in wild-type and

127 Their viral particles contain several hundred copies of a heli

128 The population of budded viral particles contains immature, maturation-intermedia

129 Here, we applied bacterial/viral particle counting, qPCR, amplicon sequencing of th

130 imary infection using genetically engineered viral particles coupled with recent technological advanc

131 graphy (ECT) to image infected cells and the viral particles cryopreserved next to them.

132 Viral particles demonstrated no change in morphology, si

133 of immunity or producers and perpetuators of viral particles depending on their content of viral geno

134 ary producers of both standard and defective viral particles during infection.

135 zed to the pulmonary tract, and newly formed viral particles egress from the apical side of the lung

136 nt adeno-associated virus (rAAV) (5 x 10(12) viral particles encoding vascular endothelial growth fac

137 rt shows that patients' CSF may be devoid of viral particles even when they test positive for COVID-1

138 bited infectivity by ~95%, and the resulting viral particles exhibited aberrant capsids.

139 envelopment and a reduction in the amount of viral particles exiting the cell.

140 ynthesized nano-inhibitor can neutralize the viral particle extracellularly and block its attachment

141 Electrospraying (ES) dissolved viral particles, followed by charge reduction and size a

142 ntiviral strategies and for utilizing benign viral particles for gene therapy.

143 but how LysRS is redirected from the MSC to viral particles for packaging is unknown.

144 d for HCV RNA replication and is involved in viral particle formation and regulation of host pathways

145 iption step of the viral genome prior to HK2 viral particle formation and/or in the infected cells.

146 owed that F-driven, M-driven, and M/F-driven viral particle formation enhanced the recruitment of G i

147 structures of these nAbs bound to all three viral particle forms-the mature virion, A-particle, and

148 Instead, ZCL278 appears to redistribute viral particles from endosomal to lysosomal compartments

149 into the cells and release of newly produced viral particles from infected cells.

150 hibitor that prevents the release of nascent viral particles from infected cells.

151 For this purpose, we used partially purified viral particles from isolate MUT4330 of Penicillium aura

152 ated CD4 downregulation is the protection of viral particles from neutralization by commonly elicited

153 s attachment to cells and reduced release of viral particles from the surface of infected cells).

154 tivated during, or shortly after, budding of viral particles from the surface of infected cells.

155 athway for the transport of single enveloped viral particles from the trans-Golgi network within smal

156 f viruses with the topology of an individual viral particle H3N2 analyzed.

157 nv) glycoprotein, incorporation into foreign viral particles has been shown to be an active process,

158 Historically, averaged bulk analysis of viral particles has been the primary method to quantitat

159 ) are still largely unknown since infectious viral particles have never been isolated from the infect

160 er, the extent to which the decomposition of viral particles (i.e., organic material of viral origin)

161 s on the composition and organization of the viral particle.IMPORTANCE Tailless viruses of the family

162 en genes are used to assemble and form a new viral particle in the host cell it infects.

163 sis of influenza viruses H3N2 with LOD of 13 viral particles in 1 mul, what is the lowest LOD for ana

164 increasing the intracellular accumulation of viral particles in a mutually exclusive fashion.

165 families can be incorporated into nonnative viral particles in a process termed pseudotyping; howeve

166 ZIKV ribonucleic acid (RNA), and infectious viral particles in different organs of a deceased newbor

167 e fluorescent signals correlated with single viral particles in enclosed vesicular compartments or su

168 mation from uncultivated microbial cells and viral particles in environmental samples.

169 associated with viral production, storage of viral particles in immune complexes, and viral persisten

170 Assembly of the Gag polyprotein into new viral particles in infected cells is a crucial step in t

171 ere observed in Pompe cells; only individual viral particles in small vacuoles were seen.

172 The biopsy revealed microthrombosis and viral particles in swollen endothelial cell nuclei.

173 by electron microscopy showed no evidence of viral particles in the biopsy samples.

174 an impaired secondary assembly of enveloped viral particles in the presence of monensin.

175 By using electron cryotomography of viral particles in the presence or absence of liposomes,

176 The presence of viral particles in the renal tubular epithelium that wer

177 e origin of the infected leukocytes and free viral particles in this body fluid remain elusive.

178 nv], both administered at a dose of 5 x 1010 viral particles) in homologous and heterologous combinat

179 We show that cGAMP is incorporated into viral particles, including lentivirus and herpesvirus vi

180 limitation of this approach is that not all viral particles incorporate both markers.

181 lic components are co-opted to transport the viral particle into the cytosol.

182 involved in the transport of newly assembled viral particles into cytoplasmic vesicles, a process imp

183 a variety of direct approaches to introduce viral particles into the inner ear have been described,

184 nv) glycoprotein, incorporation into foreign viral particles is an active process, but it does not ap

185 A segments of influenza A viruses (IAV) into viral particles is coordinated by segment-specific packa

186 The maturation of HIV-1 viral particles is essential for viral infectivity.

187 ilize CP and enhance the yield of infectious viral particles is not linked to any of its previously k

188 ism underlying packaging of genomic RNA into viral particles is not well understood for human parecho

189 The study of this issue in the context of viral particles is particularly problematic as conventio

190 signals-thereby increasing the NA content on viral particles-is a viable strategy for improving the i

191 rting increased SR-BI-receptor dependency of viral particles isolated from humanized mice compared to

192 entral paradigm within virology is that each viral particle largely behaves as an independent infecti

193 s important for the production of infectious viral particles, likely through its role in virus assemb

194 scular dose of high-dose vaccine (5 x 10(10) viral particles), low-dose vaccine (2.5 x 10(10) viral p

195 This work provides insight into how viral particles maintain infectivity in the environment.

196 HIV-1 protease is an essential enzyme for viral particle maturation and is a target in the fight a

197 d conformational switching is reminiscent of viral particle maturation and may represent a commonly u

198 s) have suggested that IN can also influence viral particle maturation.

199 come of infection by low and high numbers of viral particles may have important implications for our

200 unction (plaque-forming units, normalized to viral particles measured by unglycosylated capsid protei

201 unt the spread of viral infection by coating viral particles, mediating uptake by immune cells, or bl

202 P on the surfaces of both infected cells and viral particles might be exploited therapeutically.

203 rotein detection was approximately 2 x 10(5) viral particles/mL, making it an attractive alternative

204 stigate the link between HIV-1 integrase and viral particle morphogenesis.

205 ated virus serotype 9 encoding PDE4B (10(12) viral particles/mouse) had a ~50% increase in cardiac cA

206 sid protein and/or glycoprotein to visualize viral particle movement in neurons.

207 uncultured bacteria, archaea, protists, and viral particles, obtained directly from marine and soil

208 09 viral particles) to a high dose (5 x 1010 viral particles) occurred after the first 16 participant

209 re of the complete ASFV virion, comprising a viral particle of multiple layers, and resolve the major

210 on, was utilized to deliver 5 x 10(13) total viral particles of an Adenoviral firefly luciferase vect

211 rthern blotting, and crystalline lattices of viral particles of approximately 26-nm diameter were obs

212 om the endoplasmic reticulum (ER), such as a viral particle or cellular aggregate, likely induces mec

213 a human Gut Virome Database (GVD) from 2,697 viral particle or microbial metagenomes from 1,986 indiv

214 TG2 inhibition by either a viral particle or pharmacological approach attenuated be

215 eive ChAdOx1 nCoV-19 at a dose of 5 x 10(10) viral particles or MenACWY as a single intramuscular inj

216 es) derived solely from incoming, exogenous, viral particles or proteins.

217 ines were primed with Ad26.ZEBOV (5 x 10(10) viral particles) or MVA-BN-Filo (1 x 10(8) median tissue

218 l particles), low-dose vaccine (2.5 x 10(10) viral particles), or placebo.

219 g light on molecular aspects of tick-derived viral particles, our data illustrate the importance of c

220 nctionally characterize the in vivo produced viral particles, particularly regarding how lipoprotein

221 gimens of trivalent Ad26.Mos.HIV (5 x 10(10) viral particles per 0.5 mL) combined with 250 mug adjuva

222 dose of nadofaragene firadenovec (3 x 10(11) viral particles per mL).

223 a gene therapy solution containing 1 x 1011 viral particles performed unilaterally.

224 ng studies revealed that GPx8 is involved in viral particle production but not in HCV entry or RNA re

225 V lytic transcripts and proteins, as well as viral particle production by activating NF-kappaB signal

226 The ability to generate viral particles pseudotyped with SARS-COV-2 Spike is use

227 Therefore, the proposed direct EV71 viral particle quantification method can be rapidly perf

228 PV18 "marker" genomes could be packaged into viral particles (quasivirions) and used to infect primar

229 ellular humoral response relies on opsonized viral particles reaching the cytosol intact but the anti

230 Live cell imaging of single viral particles revealed that KF116 treatment during vir

231 of EBV lytic proteins and the production of viral particles, revealing that autophagy is critical to

232 The secreted viral particles showed no apparent change in protein con

233 oteins, not incorporated into the infectious viral particle, specifically the viral cysteine-like pro

234 An important aspect of viral particle stability for double-stranded DNA viruses

235 To explore factors that influence viral particle stability, we isolated a mutant polioviru

236 oup received two doses containing 5 x 10(10) viral particles (standard dose; SD/SD cohort); a subset

237 crucial for the efficient production of KSHV viral particles, suggesting that the targeted interferen

238 Ultraviolet irradiation of viral particles suppressed HBV infectivity but not the i

239 h VZV produced fewer defective or incomplete viral particles than MRC-5 cells.

240 ility to IFN-alpha, NT viruses produced more viral particles than TF viruses.

241 us incorporated into a replication-defective viral particle that contains a sensitive reporter system

242 nary structure located at the surface of the viral particle that spans adjacent envelope (E) proteins

243 tion of some viral ORFan proteins within the viral particle that will be helpful for understanding th

244 IV-1-infected pre-DCs produce new infectious viral particles that accumulate in intracellular compart

245 al virus particles relative to the number of viral particles that can form plaques in culture has bee

246 otal virus genomes relative to the number of viral particles that can form plaques in culture is much

247 e inner nuclear membrane forming perinuclear viral particles that subsequently fuse with the outer nu

248 ssion bottleneck is defined as the number of viral particles that transmit from one host to establish

249 s the only protein exposed on the surface of viral particles, the spike glycoprotein GP is the unique

250 utralized all known ebolaviruses by coopting viral particles themselves for endosomal delivery and co

251 f the transfected cells, which contained HK2 viral particles, then were added to target cells, and th

252 They assemble an immature viral particle through oligomerization of full-length Ga

253 d HBV (sHBV), which required purification of viral particles through ultracentrifugation or PEG preci

254 ntribute to preserving the infectiousness of viral particles, thus revealing a novel Vpu function tha

255 ression of TIM-1 causes HIV-1 Gag and mature viral particles to accumulate on the plasma membrane.

256 We exploit the biotinylated viral particles to generate two distinct AAV interactome

257 in the conversion of immature noninfectious viral particles to mature infectious virions.

258 -1 complex controls delivery of internalised viral particles to multivesicular endosomes.

259 infection directly but are able to sensitize viral particles to neutralization by otherwise nonneutra

260 tification of the ratio of genome-containing viral particles to PFU indicated that Slfn11 impairs WNV

261 enveloped virus release by tethering budded viral particles to the plasma membrane.

262 ally infected CD4(+) T cells transfer p19(+) viral particles to the surface of allogeneic DCs via cel

263 These macrophages are critical in amplifying viral particles to trigger type I interferon production

264 An escalation from a low dose (5 x 109 viral particles) to a high dose (5 x 1010 viral particle

265 ntibodies: the potential ability to opsonize viral particles, to direct antibody-dependent cellular c

266 The number of viral particles transmitted from one host to another, kn

267 lytic phase of the life cycle, the maturing viral particles undergo orchestrated translocation to sp

268 to specific cell receptors, which results in viral particles undergoing sequential conformational cha

269 ith ChAd3-EBO-Z: Malians received 1 x 10(10) viral particle units (pu), 2.5 x 10(10) pu, 5 x 10(10) p

270 ith a single dose of Ad5.RSV-F at 1 x 10(11) viral particles (v.p.) elicited antibody titers 64- to 2

271 oups of 12 subjects received 10(9) to 10(11) viral particles (vp) of the Ad5HVR48.EnvA.01 vaccine (n

272 ha/Syn3 (randomly assigned 1:1 to 1 x 10(11) viral particles (vp)/mL or 3 x 10(11) vp/mL).

273 disassembly and post-uncoating processing of viral particles was markedly suppressed in CD63 or synte

274 resolving carbon and nitrogen enrichment in viral particles, we demonstrate the power of nanoSIMS tr

275 ysis of the virion composition of ORF52-null viral particles, we observed a decrease in the incorpora

276 To study the assembly of single viral particles, we tagged M and P with fluorescent prot

277 cortical thinning, high ZIKV RNA loads, and viral particles were detected, and ZIKV was subsequently

278 We found that IgG1-coated viral particles were neutralized via TRIM21, even when a

279 ns were housed in single-membraned vesicles; viral particles were not observed in autophagosomes.

280 , DNA templates, RNA molecules, proteins and viral particles were produced in an automated fashion fr

281 med between mast cells and T cells, to which viral particles were recruited, and these were required

282 Ultimately, viral particles were released from the compartment and t

283 Cs) were permissive to EV-A71 infection, and viral particles were released in a nonlytic manner.

284 We found that different types of viral particles were unevenly distributed in the nucleus

285 n a 50% increase in infectivity of cell-free viral particles when produced in 293T cells.

286 ti-VP2 (aa141-155) sera bound authentic CA16 viral particles, whereas anti-VP1 (aa208-222) sera could

287 We show that stability of viral particles (which directly relates to infectivity)

288 rporation of envelope glycoprotein into JSRV viral particles, which in turn reduces virion infectivit

289 thway is involved in the nonlytic release of viral particles, which may be useful for developing anti

290 ads to a reduction in Env incorporation into viral particles, which ultimately results in the release

291 1) in a species-specific manner by uncoating viral particles while activating early innate responses.

292 uitment of the viral RNA genome into nascent viral particles while cellular transcripts are excluded.

293 recovery from individual microbial cells and viral particles while maintaining ease of use and scalab

294 both DVG- and full-length-genome-containing viral particles, while DVG-high cells poorly produced vi

295 type 9 (AAV9) capsid, to permit labelling of viral particles with either a fluorescent dye or biotin.

296 oned by enhancing the adhesion and fusion of viral particles with target cells but not their aggregat

297 fixed pattern of gRNA organization among all viral particles, with the major and minor grooves of RNA

298 es, 2.5x10(10) viral particles, and 5x10(10) viral particles--with 20 participants in each group.

299 We demonstrate that clustered packaging of viral particles within vesicles enables multiple viral R

300 ticles, while DVG-high cells poorly produced viral particles yet strongly stimulated antiviral immuni